C5241015

The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of a study drug for respiratory syncytial virus (RSV). This study will look at the effects of multiple doses of the study drug compared to placebo and an additional medication in healthy adults.

RSV is a common and widespread cause of acute respiratory illness. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States. Currently, there is no cure or vaccine for RSV, and therapeutics are limited. There is a great medical need to develop a safe and effective treatment to help patients who become ill with this virus.

Read more below about how you can get involved and help patients breathe easier.

Card Summary Component

Who may participate

Clinical trials are key to developing potential life-changing treatments for people across the globe. But they can't happen without participants.

This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements: 

  • Willing to take a study drug
  • Willing and able to come to our facility in New Haven, CT*
  • Able to comply with all study procedures

*participants may be eligible to receive a bonus for travel, ask our staff for details

There are other requirements for participation in this study. The study staff will explain these to you during the screening process.

 

Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus. 

Condition

Healthy

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Age

18-65 years

The age a person must be to participate in a clinical trial.

Sex

All sexes

The sex of people who may participate in a clinical trial. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

Referral bonus

Up to $150

Click “learn more” for program details. Compensation may be provided on a loadable debit card or by paper check in US dollars. The New Haven PCRU reserves the right to determine method of payment, determine eligibility, or change or terminate this program at any time.

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

Card Summary Component

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.

If you choose to participate, you will stay at our facility for 22 overnights. Starting the morning after admission, you will receive one the following study interventions:

  • Doses of the study drug every 12 hours up to a total of 5 doses
  • Doses of a placebo every 12 hours up to a total of 5 doses
  • Doses of a placebo every 12 hours up to 4 doses, followed by a single dose of an additional medication 12 hours after the last placebo dose

You will receive one each of the above interventions in a randomly chosen order for a total of 3 dosing periods. All doses are given orally in the form of tablets or capsules to swallow.

Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.

Required overnight stays

22

A participant may be required to stay overnight at the PCRU for observation and study procedures. The number and length of overnight stays is determined by the design of the study.

Long-term follow up

1 phone call

Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.

How long is this study?

Up to about 50 days

This is the time between admission and final follow-up call or visit. This does not include the time between screening and dosing, which can be up to 28 days.

Compensation

Up to $7,450 upon completion of the study

Participants in clinical trials at the PCRU receive financial compensation for their participation. The amount depends on factors like length of the stay, total number of study visits, and the nature of the study procedures.

All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.

Interested in participating?

Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you. Please note: volunteers completing this form must be able to read and speak English at an 8th grade level.

You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.

For Japanese language assistance only, please call 1-833-711-9984. We apologize, our representatives cannot take calls in languages other than English or Japanese at this time.

The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.

Cancel